These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31099686)

  • 1. Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era.
    Brander D; Islam P; Barrientos JC
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():487-498. PubMed ID: 31099686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
    Iovino L; Shadman M
    Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lymphocytic leukemia treatment algorithm 2018.
    Parikh SA
    Blood Cancer J; 2018 Oct; 8(10):93. PubMed ID: 30283014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Treatment of Chronic Lymphocytic Leukemia.
    Jamroziak K; Puła B; Walewski J
    Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat E; Dreger P
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic lymphocytic leukemia: pathophysiology and current therapy].
    Takizawa J
    Rinsho Ketsueki; 2017; 58(5):471-479. PubMed ID: 28592762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
    Voorhies BN; Stephens DM
    Curr Treat Options Oncol; 2017 Feb; 18(2):12. PubMed ID: 28243993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.
    Sharma S; Rai KR
    Cancer; 2019 May; 125(9):1432-1440. PubMed ID: 30807655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
    Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
    Front Immunol; 2020; 11():594556. PubMed ID: 33312177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
    Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of elderly and unfit patients with chronic lymphocytic leukemia.
    Mauro FR; Salaroli A; Caputo MD; Colafigli G; Petrucci L; Campanelli M; Ferretti A; Guarini AR; Foà R
    Expert Rev Hematol; 2016 Dec; 9(12):1165-1175. PubMed ID: 27796157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic markers and standard management of chronic lymphocytic leukemia.
    Stilgenbauer S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
    Yeung CCS; Shadman M
    Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia.
    Cramer P; Hallek M; Eichhorst B
    Oncol Res Treat; 2016; 39(1-2):25-32. PubMed ID: 26890007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial therapy of chronic lymphocytic leukemia.
    Eichhorst B; Cramer P; Hallek M
    Semin Oncol; 2016 Apr; 43(2):241-50. PubMed ID: 27040702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C
    Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [News in therapeutic management of chronic lymphoid leukemia].
    Michallet AS; Salles G; Coiffier B; Michallet M
    Bull Cancer; 2005 Mar; 92(3):249-56. PubMed ID: 15820919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Rossi D; Gerber B; Stüssi G
    Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.